Obesity is often associated with vitamin D deficiency and secondary hyperparathyroidism. Vitamin D supplementation typically leads to the reductions in serum parathyroid hormone (PTH) levels, as shown in normal weight individuals. Meanwhile, the dose of vitamin D supplementation for the suppression of PTH may differ in overweight and obese adults. We conducted a systematic review and meta-analysis of randomized controlled trials to determine the dose of vitamin D supplementation required to suppress PTH levels in overweight/obese individuals. We identified 18 studies that examined overweight or obese healthy adults who were supplemented with varying doses of vitamin D3. The primary outcomes examined were changes in PTH and serum 25-hydroxyvitamin D (25OHD) levels from baseline to post-treatment. The results of the meta-analysis showed that there was a significant treatment effect of vitamin D supplementation on PTH, total standardized mean difference (SMD) (random effects) = −0.38 (95% CI = −0.56 to −0.20), t = −4.08, p < 0.001. A significant treatment effect of vitamin D supplementation was also found on 25OHD, total SMD (random effects) = 2.27 (95% CI = 1.48 to 3.06) t = 5.62, p < 0.001. Data from available clinical trials that supplemented adults with D3 ranging from 400 IU to 5714 IU, showed that 1000 IU of vitamin D supplementation best suppressed serum PTH levels, total SMD = −0.58, while vitamin D supplementation with 4000 IU showed the greatest increase in serum 25OH levels. Vitamin D and calcium supplementation of 700 IU and 500 mg, respectively, also showed a significant treatment effect on the suppression of PTH with a total SMD = −5.30 (95% CI = −9.72 to −0.88). In conclusion, the meta analysis of available clinical trials indicates that 1000 IU vitamin D supplementation can suppress serum PTH levels, while 4000 IU of vitamin D was associated with the largest increase in serum 25OHD levels in the overweight and obese population.

Magnesium (Mg) intake is an important indication of an individual’s Mg status, but no validated food frequency questionnaire (FFQ) to assess intake currently exists. The purpose of this study was to develop and investigate the validity of a semi-quantitative Mg food frequency questionnaire (MgFFQ) against a 14-day food diary to assess average daily Mg intakes. In this cross-sectional study, 135 adults aged 18 to 75 completed the 33-item MgFFQ and a 14-day food diary to assess their Mg intakes. Coefficients of variance, Pearson’s correlation coefficients, and/or Spearman’s rank correlation coefficient tests were used to determine the relationship between the MgFFQ and the average Mg intake from the 14-day food diary among all participants, men, women, age groups, and body mass index (BMI) groups. The correlation between the MgFFQ and the 14-day food diary was significant (p < 0.05) for all participants (r = 0.798), men (r = 0.855), women (r = 0.759), normal weight (r = 0.762), overweight (r = 0.858), and obese (r = 0.675) weight statuses, and in all age groups. The calcium to magnesium intake (Ca:Mg) ratio in all participants was higher than optimal, 3.39 (2.11). Our results suggest that the MgFFQ is a valid method to capture Mg intake over an extended period of time, therefore acting as a valuable tool to quickly determine Mg intake.